Clinical trial · Interventional
Eradication of Prostate Cancer Using F-989
Phase II Eradication of Prostate Cancer Using F-989
NCT01987999CI-TRIAL-00040745completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to confirm the findings of an early study with prostate cancer and to expand our knowledge of treating prostate cancer using F-989.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acetogenins | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Acetogenins
- description
- Acetogenins twice (BID) per day for 12 months
- interventionNames
- Dietary Supplement: Acetogenins
Primary outcomes (1)
- measure
- Gleason Score
- timeFrame
- 1 year
- description
- A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate.
Secondary outcomes (1)
- measure
- Prostate Specific Antigens (PSA)
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of prostate cancer * Referred to the study by their treating physician Exclusion Criteria: \- Any type of treatment before starting study
References
Publications (0)
Data not yet available
No reference posted for this study.